Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886355 | 0.78 | — | — | |
| SCHEMBL5731593 | 0.76 | SIGMAR1 (0.49) | SIGMAR1GNAI3GNAO1GNAI1CA12 | |
| SCHEMBL10643920 | 0.75 | SIGMAR1 (0.42) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL6066343 | 0.75 | GNAI3 (0.38) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL4724864 | 0.74 | SIGMAR1 (0.42) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL3802269 | 0.74 | — | — | |
| SCHEMBL4763916 | 0.73 | SIGMAR1 (0.38) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL27855514 | 0.73 | SIGMAR1 (0.35) | SIGMAR1GNAI3GNAO1GNAI1CA12 | |
| SCHEMBL4167488 | 0.72 | CA2 (0.32) | CA12CA1CA9 | |
| SCHEMBL4722693 | 0.71 | SIGMAR1 (0.41) | SIGMAR1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8313756-B1 | Urea compositions and their methods of manufacture | Fougera Pharmaceuticals, Inc. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8158138-B1 | Urea compositions and their methods of manufacture | Fougera Pharmaceuticals, Inc. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1651266-B1 | ADMINISTRATION OF ANTI-TNF-ALPHA F(AB')2 ANTIBODY FRAGMENTS | SILANES SA DE CV LAB (MX) | 2010-03-03 | — | — | EP | disclosed |
| US-20060210563-A1 | Administration of anti-cytokine f(ab')2 antibody fragments | LOPEZ DE SILANES JUAN | 2006-09-21 | — | — | US | disclosed |
| EP-1651266-A4 | ADMINISTRATION OF ANTI-CYTOKINE F(AB')2 ANTIBODY FRAGMENTS | SILANES SA DE CV LAB (MX) | 2006-08-02 | — | — | EP | disclosed |
| US-7074832-B2 | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use | BRADLEY PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-7067556-B2 | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use | BRADLEY PHARMACEUTICALS, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1651266-A1 | ADMINISTRATION OF ANTI-CYTOKINE F(AB')2 ANTIBODY FRAGMENTS | Lopez de Silanes, Juan (MX) | 2006-05-03 | — | — | EP | disclosed |
| US-6960615-B2 | Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use | BRADLEY PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2005009464-A1 | ADMINISTRATION OF ANTI-CYTOKINE F(AB')2 ANTIBODY FRAGMENTS | LOPEZ DE SILANES JUAN (MX) | 2005-02-03 | — | — | WO | disclosed |
| WO-2003039453-A2 | NOVEL BENZOYL PEROXIDE COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE | BRADLEY PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| US-20030064084-A1 | Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use | BRADLEY PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2003026639-A1 | NOVEL COMPOSITIONS CONTAINING ANTIMICROBIALS AND UREA FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS AND METHODS FOR THEIR USE | BRADLEY PHARMACEUTICALS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030064969-A1 | Novel compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use | BRADLEY PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-6495602-B1 | COMPRISES UREA, ASTRINGENT (CALCIUM ACETATE AND/OR ALUMINUM SULFATE), AND LIDOCAINE AND/OR CORTICOSTEROID (HYDROCORTISONE) TO IMPROVE HEALING OF SKIN | BRADLEY PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| US-6429231-B1 | TOPICAL FORMULATION COMPRISED OF SULFACETAMIDE, UREA, AND SULFUR FOR USE IN TREATING ACNE; SMOOTH TEXTURE; SUITABLE FOR USE IN COSMETICS | BRADLEY PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| US-6380236-B2 | TISSUE SOFTENING COMPOSITION OF UREA AND DERMATOLOGICALLY ACCEPTABLE EXCIPIENTS; AND AN ANTIFUNGAL AGENT | BRADLEY PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| US-20010049386-A1 | Method of treating onychomycosis | BRADLEY PHARMACEUTICALS, INC. (US) | 2001-12-06 | — | — | US | disclosed |
| US-6281239-B1 | TISSUE SOFTENING COMPOSITION CONTAINING UREA AND AN ANTIFUNGAL COMPOSITION | BRADLEY PHARMEACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| US-5919470-A | 21 TO ABOUT 40 WT-% UREA WITH SKIN PROTECTANTS OF AN OLEAGINOUS NATURE FOR TREATING A VARIETY OF DERMATOLOGICAL CONDITIONS MANIFESTED BY DRY SKIN. THE COMPOSITION DOES NOT REQUIRE USE OF TRADITIONAL PRESERVATIVES. | BRADLEY PHARMACEUTICALS, INC. (US) | 1999-07-06 | — | — | US | disclosed |